# Danielle Peyton

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/danielle-peyton-person
Canonical HTML page: https://gethealthbrief.com/entity/danielle-peyton-person

## Recent coverage (1 stories)

### Celcuity Stock Tanks 17.6% on Late Q3 Cancer Drug Launch; Pomerantz Investigates
2026-07-20 12:39:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Pomerantz LLP probes Celcuity after FDA-approved breast cancer therapy Revtorpyk sees delayed Q3 2026 commercial launch, sending shares down 17.6%. Analysts question prior launch readiness; health investors weigh biotech regulatory and execution risks.
Full story: https://gethealthbrief.com/story/celcuity-revtorpyk-launch-delay-pomerantz-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.